Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(25%)
Results Posted
200%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_4
2
50%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Recruiting1
Completed1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (25.0%)
Phase 42 (50.0%)
N/A1 (25.0%)

Trials by Status

recruiting125%
completed125%
unknown125%
terminated125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_4

DESIFOR-EXPAND (MHIF)

NCT06804980
terminatednot_applicable

STIP: Statin Trial for Influenza Patients

NCT00970606
completedphase_3

12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe

NCT00525824
unknownphase_4

Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)

NCT00885872

Clinical Trials (4)

Showing 4 of 4 trials
NCT06804980Phase 4

DESIFOR-EXPAND (MHIF)

Recruiting
NCT00970606Not Applicable

STIP: Statin Trial for Influenza Patients

Terminated
NCT00525824Phase 3

12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe

Completed
NCT00885872Phase 4

Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4